CAPR - CAPRICOR THERAPEUTICS, INC.
IEX Last Trade
14.235
0.165 1.159%
Share volume: 11,998
Last Updated: Fri 27 Dec 2024 08:29:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$14.07
0.17
1.17%
Fundamental analysis
22%
Profitability
25%
Dept financing
11%
Liquidity
50%
Performance
15%
Performance
5 Days
-0.35%
1 Month
-26.05%
3 Months
41.51%
6 Months
203.45%
1 Year
177.17%
2 Year
319.05%
Key data
Stock price
$14.24
DAY RANGE
$13.87 - $14.55
52 WEEK RANGE
$3.80 - $23.40
52 WEEK CHANGE
$187.93
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Linda Marbán
Region: US
Website: capricor.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: capricor.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Capricor Therapeutics, Inc. focuses on the development of transformative cell and exosome-based therapeutics. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD) The company also develops CAP-2003 that is in pre-clinical development for the. treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.
Recent news